Clinical Trials on Navigation, Spatial in Denmark

Total 11 results

Zealand University Hospital
UNEEG Medical A/S; Technical University of Denmark

Completed

Subcutaneous EEG in Epilepsy

Temporal Lobe Epilepsy

Denmark
Oticon Medical

Completed

Clinical Survey of Oticon Medical Healing Cap

Conductive Hearing Loss | Mixed Hearing Loss | Unilateral Partial Deafness

Denmark
UCB Pharma

Completed

Trial to Assess Lacosamide as the First add-on Anti-epileptic Drug Treatment in Patients With Partial-onset Seizures

Partial Epilepsies

United States, Austria, Bulgaria, Czechia, Denmark, Finland, France, Greece, Italy, Mexico, Romania, Russian Federation, Spain, Switzerland, Turkey
Eisai Inc.

Completed

A Double-blind Study to Compare the Efficacy and Safety of Zonisamide and Carbamazepine as Monotherapy, in Newly Diagnosed Partial Epilepsy

Epilepsy

Australia, France, Poland, Germany, Spain, India, Serbia, Greece, Korea, Republic of, Russian Federation, Taiwan, Hungary, Italy, Sweden, Denmark, Slovakia, United Kingdom, South Africa
Eisai Inc.

Completed

A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)

Partial Onset Seizures

Germany, Sweden, Norway, Austria, Denmark
Eisai Limited

Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Idiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic Seizures

France, Spain, Italy, Denmark, Germany, Portugal, Russian Federation
Eisai Inc.

Completed

A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

Partial Onset Seizures

France, United Kingdom, Germany, Denmark, Czech Republic, Norway, Sweden, Ireland
Eisai Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

Partial-onset Seizures | Pediatric Epileptic Syndrome

United States, Spain, France, Belgium, Czechia, Denmark, Germany
Eisai Inc.

Completed

Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures

Epilepsy

Greece, Italy, Spain, Sweden, Korea, Republic of, Germany, Australia, France, Switzerland, Slovakia, Poland, Taiwan, Hungary, Serbia, India, United Kingdom, Denmark, Russian Federation, South Africa, Montenegro
Hoffmann-La Roche
Chugai Pharmaceutical Co.

Recruiting

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo)

NMDAR Autoimmune Encephalitis | LGI1 Autoimmune Encephalitis

United States, Korea, Republic of, China, Japan, Czechia, Italy, Poland, Austria, Brazil, Argentina, Netherlands, Taiwan, Denmark, France, Ghana
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more

Clinical Trials on Navigation, Spatial in Denmark

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations